Grunenthal completed the acquisition of Crestor from AstraZeneca for $350m.

Grunenthal, a pharmaceutical company, completed the acquisition of Crestor, a statin, a lipid-lowering medicine, from AstraZeneca, a biopharmaceutical company, for $350m. “This agreement supports the management of our mature medicines to enable reinvestment into the pipeline and bringing new, innovative treatments to patients. Grünenthal previously acquired the rights to several established AstraZeneca medicines and is well placed to ensure continued access to Crestor for patients across Europe," Ruud Dobber, Grunenthal BioPharmaceuticals Business Unit Executive Vice President.